Indivior Pharmaceuticals (INDV) Total Current Liabilities (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Total Current Liabilities of $779.0 million for Q1 2026, down 22.49% year-over-year from $1.0 billion in Q1 2025, and down 14.77% quarter-over-quarter from $914.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Total Current Liabilities (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $779.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 22.49% year-over-year to $779.0 million; the TTM figure through Mar 2026 stood at $779.0 million (down 22.49% YoY), while the FY2025 annual figure was $914.0 million, down 1.08% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $779.0 million, down from $914.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $1.3 billion in Q4 2023, with the low at $779.0 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $985.0 million (2025), against an average of $992.9 million.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities grew 26.74% in 2022, then declined 27.87% in 2024.
- Indivior Pharmaceuticals' Total Current Liabilities stood at $1.0 billion in 2022, then climbed by 25.71% to $1.3 billion in 2023, then slipped by 27.87% to $924.0 million in 2024, then dropped by 1.08% to $914.0 million in 2025, then declined by 14.77% to $779.0 million in 2026.
- Business Quant data shows INDV's Total Current Liabilities at $779.0 million in Q1 2026, $914.0 million in Q4 2025, and $965.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.79 Bn |
| 10 | Indivior Pharmaceuticals | 4.53 Bn | 4.31 Bn | 294.00 Mn | 868.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 868.00 Mn |
| Mar 31, 2026 | 779.00 Mn |
| Dec 31, 2025 | 914.00 Mn |
| Sep 30, 2025 | 965.00 Mn |
| Jun 30, 2025 | 1.06 Bn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 924.00 Mn |
| Dec 31, 2023 | 1.28 Bn |
| Dec 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 804.00 Mn |